The CI-AKI group more frequently used calcium channel blockers before admission, and more frequently received coumarin derivatives and mineralocorticoid receptor antagonists (MRA) during hospitalization (Table 2 and Online Resource 7). This evidence concerns the gene NR3C2 and acute kidney injury.